A systematic review in Frontiers in Nutrition describes mechanisms through which berberine may affect metabolism and inflammation in fatty liver disease. The authors say clinical use remains limited by poor absorption and differences in patients’ responses.
Researchers from Hunan University of Chinese Medicine analyzed publications on berberine and metabolic dysfunction-associated steatotic liver disease. They retrieved 341 and 624 records from two scientific databases. The paper maps research directions and discusses possible mechanisms of action.
The authors say studies have linked berberine to regulation of fat and glucose metabolism, insulin sensitivity and inflammatory processes. The review also examines research on the gut microbiome’s relationship with the liver, the intestinal barrier and oxidative stress.
The authors note that some clinical studies have reported reduced liver fat and improved metabolic indicators in patients taking berberine. However, a literature review by itself does not establish that the substance is an effective treatment. The paper highlights low oral bioavailability and substantial variation in responses among patients.
The researchers call for large, long-term randomized trials to assess efficacy and safety. The publication discusses research prospects and limitations, rather than recommending that people take berberine.